Literature DB >> 6158170

In vivo behaviour of gamma globulin preparations.

A Morell, B Schürch, D Ryser, F Hofer, F Skvaril, S Barandun.   

Abstract

Metabolic properties of standard gamma globulin (St-GG) and of several gamma globulin (GG) preparations for intravenous use were analyzed in radioactive tracer studies. The in vivo behaviour of St-GG was investigated in 16 probands and found to be comparable to that of normal IgG. The kinetics of the resorption of St-GG from intramuscular deposits, its elimination from the intravascular compartment and from the body were studied in 2 probands. Metabolic properties of GG preparations for intravenous use were compared with those of St-GG in 3-4 probands after simultaneous injection of 125I- and 131I-labelled tracer doses. Important differences in the half-times of intravascular survival, in the rates of catabolism and in the distribution in the body were noticed for most of the preparations for intravenous use except for an improved acid-treated (pH 4) GG, the in vivo behaviour of which was similar to that of St-GG.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158170     DOI: 10.1111/j.1423-0410.1980.tb02367.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  13 in total

1.  Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.

Authors:  R I Schiff; L W Williams; R P Nelson; R H Buckley; W Burks; R A Good
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

2.  Increased half-life of gammaglobulin after prolonged intravenous replacement therapy.

Authors:  A M Lever; P L Yap; B Cuthbertson; R Wootton; A D Webster
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

3.  Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.

Authors:  R I Schiff; C Rudd
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

4.  Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study.

Authors:  W Glinz; P J Grob; U E Nydegger; T Ricklin; F Stamm; D Stoffel; A Lasance
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

5.  Quality control in the production of an immunoglobulin for intravenous use.

Authors:  A Gardi
Journal:  Blut       Date:  1984-06

6.  Intravenous immunoglobulin therapy: new aspects and outlook.

Authors:  P Imbach; S Barandun; C Baumgartner; G Gaedicke; A Hirt; H P Wagner
Journal:  Blut       Date:  1984-06

7.  Turnover rate of anti-D IgG injected during pregnancy.

Authors:  J Eklund; M Hermann; H Kjellman; P Pohja
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-20

8.  Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases.

Authors:  A Sansome; V Dubowitz
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

9.  Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.

Authors:  J R Groothuis; E A Simoes; M V Lehr; A A Kramer; V G Hemming; W J Rodriguez; J Arrobio; R C Welliver; G R Siber
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes.

Authors:  J Björkander; C Wadsworth; L A Hanson
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.